Pulmonary hypertension associated with bronchopulmonary dysplasia. Review

Abstract

Bronchopulmonary dysplasia (BPD) is a multifactorial chronic disease highly raised during the last two decades. It mostly affected newborns with extremely or very low birth weight. BPD rate crucially increased up to 68% among premature who were born earlier than 29 weeks of gestational age. Lung hypertension is one of the severe complications with a high proportion of disability and mortality in the late stage of diagnostics. Our review discussed modern risk factors, distribution, pathogenesis, and criteria of the diagnoses of lung hypertension in BPD. Prematurity and duration of mechanical ventilation are not the main risk factors. Those, one from two newborns with necrotizing enterocolitis, could lead to the stenosis of the lung veins and lung hypertension. There is no optimal strategy for the diagnostics and time of the screening in the group of premature newborns with BPD. The leading goal in the treatment of lung hypertension is recovering of pulmonary insufficiency. The second purpose is a decrease of hypoxic/hypercapnic vasoconstriction and the improvement of the intrapulmonary gas exchange. Recently, we do not know universal treating tools for lung hypertension in BPD that give us the chance to perform new research.

Keywords:pulmonary hypertension, bronchopulmonary dysplasia, diagnostics, treatment

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

For citation: Zelyanina E.A., Bokeriya E.L. Pulmonary hypertension associated with bronchopulmonary dysplasia. Review. Neona-tologiya: novosti, mneniya, obuchenie [Neonatology: News, Opinions, Training]. 2020; 8 (2): 21-7. DOI: 10.33029/2308-2402-2020-8-2-21-27 (in Russian)

References

1. Altit G., Dancea A., Renaud C., et al. Pathophysiology, screening and diagnosis of pulmonary hypertension in infants with bronchopulmonary dysplasia - a review of the literature. Paediatr Respir Rev. 2017; 23: 16-26.

2. Ovsyannikov D.Yu., Komleva N.A., Oboladze T.B. Modern algorithms of bronchial dysplasia diagnosis. Voprosy diagnostiki v pediatrii [Problems of Diagnostics in Pediatrics]. 2011; 3 (1): 12-20. (in Russian)

3. Stuart B.D., Sekar P., Coulson J.D., et al. Health-care utilization and respiratory morbidities in preterm infants with pulmonary hypertension. J Perinatol. 2013; 33 (7): 543-7.

4. Khemani E., McElhinney D.B., Rhein L., et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: Clinical features and outcomes in the surfactant era. Pediatrics. 2007; 120 (6): 1260-9.

5. Rosenzweig E.B., Abman S.H., Adatia I., et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019; 53 (1).

6. Abman S.H., Hansmann G., Archer S.L., et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015; 132 (21): 2037-99.

7. Hansmann G., Apitz C., Abdul-Khaliq H., et al. Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016: 102 (2): 86-100.

8. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Internat. Eur Heart J. 2009; 30 (20): 2493-537.

9. Kim D.H., Kim H.S., Choi C.W., et al. Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonatology. 2011; 101 (1): 40-6.

10. Check J., Gotteiner N., Liu X., et al. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol. 2013; 33 (7): 553-7.

11. Bhat R., Salas A.A., Foster C., et al. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics. 2012; 129 (3): 682-9.

12. An H.S., Bae E.J., Kim G.B., et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J. 2010; 40 (3): 131-6.

13. Collaco J.M., Romer L.H., Stuart B.D., et al. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol. 2012; 47 (11): 1042-53.

14. Ivy D.D., Abman S.H., Barst R.J., et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013; 62 (25): 117-26.

15. Balasubramaniam V., Mervis C.F., Maxey A.M., et al. Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2007; 292 (5): 1073-84.

16. Mourani P.M., Ivy D.D., Rosenberg A.A., et al. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr. 2008; 152 (2): 291-3.

17. Heching H.J., Turner M., Farkouh-Karoleski C., et al. Pulmonary vein stenosis and necrotising enterocolitis: Is there a possible link with necro-tising enterocolitis? Arch Dis Child Fetal Neonatal Ed. 2014; 99 (4): 1-4.

18. Krishnan U., Feinstein J.A., Adatia I., et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr. 2017; 188: 24-34.

19. Abman S.H., Collaco J.M., Shepherd E.G., et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017; 181: 12-28.

20. Mourani P.M., Sontag M.K., Younoszai A., et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics. 2008; 121 (2): 317-25.

21. Carlton E.F., Sontag M.K., Younoszai A., et al. Reliability of echocardiographic indicators of pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. J Pediatr. 2017; 186: 29-33.

22. Mourani P.M., Sontag M.K., Younoszai A., et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2015; 191 (1): 87-95.

23. Nagiub M., Lee S., Guglani L. Echocardiographic assessment of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review of literature and a proposed algorithm for assessment. Echocardiography. 2015; 32 (5): 819-33.

24. Nekludova G.V., Naumenko J.K. Echocardiography for the diagnosis of pulmonary hypertension. Prakticheskaya pul’monoliya [Practical Pulmonology]. 2015; (2): 48-56. (in Russian)

25. Degtyareva E.A., Ovsyannikov D.Yu., Zaitseva N.O., et al. Risk factors and echocardiographic diagnosis of pulmonary hypertension in children with bronchopulmonary dysplasia. Vestnik RUDN. Seriya: Meditsina [Bulletin of the Russian University of Peoples’ Friendship. Series: Medicine]. 2017; 21 (2): 259-69. (in Russian)

26. Mahgoub L., Kaddoura T., Kameny A.R., et al. Pulmonary vein stenosis of ex-premature infants with pulmonary hypertension and bronchopulmonary dysplasia, epidemiology, and survival from a multicenter cohort. Pediatr Pulmonol. 2017; 52 (8): 1063-70.

27. Abman S.H. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed. 2002; 87 (1): 15-8.

28. Clouse B.J., Jadcherla S.R., Slaughter J.L. Systematic review of inhaled bronchodilator and corticosteroid therapies in infants with bronchopulmonary dysplasia: Implications and future directions. PLoS One. 2016; 11 (2): 1-18.

29. Kim G.B. Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr. 2010; 53 (6): 688-93.

30. Barrington K.J., Finer N., Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2010; 12.

31. Wardle A.J., Wardle R., Luyt K., et al. The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Arch Dis Child. 2013; 98 (8): 613-7.

32. Backes C.H., Reagan P.B., Smith C.V., et al. Sildenafil treatment of infants with bronchopulmonary dysplasia-associated pulmonary hypertension. Hosp Pediatr. 2016; 6 (1): 27-33.

33. Mourani P.M., Sontag M.K., Ivy D.D., et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009; 154 (3): 379-84.

34. Trottier-Boucher M.N., Lapointe A., Malo J., et al. Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. Pediatr Cardiol. 2015; 36 (6): 1255-60.

35. Kadmon G., Schiller O., Dagan T., et al. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. Pediatr Pul-monol. 2017; 52 (1): 77-83.

36. Baker C.D., Abman S.H., Mourani P.M. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol. 2014; 27 (1): 8-16.

37. Alipour M.R., Lookzadeh M.H., Namayandeh S.M., et al. Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension. Iran J Pediatr. 2017; 27 (1): 1-4.

38. Sehgal A., Krishnamurthy M.B., Clark M., et al. ACE inhibition for severe bronchopulmonary dysplasia - an approach based on physiology. Physiol. Rep. 2018; 6, N 17: 1-10.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Degtyarev Dmitriy Nikolaevich
Doctor of Medical Sciences, Professor, Deputy Director for Scientific Research of the V.I. Kulakov Obstetrics, Gynecology and Perinatology National Medical Research Center of Ministry of Healthсаre of the Russian Federation, Head of the Chair of Neonatology at the Clinical Institute of Children's Health named after N.F. Filatov, I.M. Sechenov First Moscow State Medical University, Chairman of the Ethics Committee of the Russian Society of Neonatologists, Moscow, Russian Federation

ORCID iD 0000-0001-8975-2425

Journals of «GEOTAR-Media»